 HIGHLANDS RANCH, Colo., Aug. 17, 2021 GLOBE NEWSWIRE -- Vivos Therapeutics, Inc. the Company or Vivos NASDAQ: VVOS, a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea OSA, today announced a more detailed summary of the national study results announced by the Company on July 13, 2021, is now available on the Companys website at: 